We retrospectively studied vancomycin taper and pulse treatment on 100 consecutive, evaluable patients with recurrent Clostridium difficile infection. Following taper to once-daily vancomycin dosing, 22 of 36 patients (61%) who received everyother-day dosing (QOD) and 50 of 64 (81%) who received QOD followed by every-third-day dosing were cured (P = .03).
The current Infectious Diseases Society of America (IDSA)/ Society for Healthcare Epidemiology of America (SHEA) guidelines for treating recurrent Clostridium difficile infection (rCDI) recommend treatment of the first recurrence with the same regimen used for treatment of the initial episode with a caveat of using oral vancomycin if the recurrence is severe, and treating further recurrences with oral vancomycin in a tapered and pulsed fashion [1] . Despite this recommendation, very few studies of vancomycin taper and/or pulse dosing have been reported that would allow estimation of optimal regimens and expected outcomes [2, 3] . Our clinic has been a referral center for patients with rCDI for the last decade. Although we have used several treatment strategies for patients with multiple recurrences, including a post-vancomycin rifaximin chaser [4, 5] and a fidaxomicin taper and pulse [6] , a carefully observed vancomycin taper and pulse (VAN-TP) regimen has been the initial treatment strategy for management of these patients who have failed other regimens. In this study, we describe our observational experience using oral VAN-TP dosing regimens with careful follow-up in the management of 100 consecutive patients with rCDI.
METHODS
A records review was conducted for all patients seen at our clinic between 1 January 2009 and 31 December 2014. These patients were seen monthly with more frequent contacts as needed. All patients had at least 1 of their prior CDI episodes confirmed with a C. difficile stool assay (prior to July 2011 by toxin A/B immunoassay and afterward by polymerase chain reaction). Recurrent CDI was defined as ≥2 CDI episodes at the time of referral. Following referral, these patients were treated with a VAN-TP regimen defined as a taper of vancomycin to once daily, followed by every-other-day (QOD) dosing, or once daily followed by QOD followed by every-third-day (Q3D) dosing for at least 2 weeks. All patients had follow-up documented for at least 90 days after completion of the VAN-TP regimen. Recurrent CDI was defined as recurrence of diarrheal symptoms requiring re-treatment with a CDI-specific agent. Some patients noted a transient recurrence of symptoms near the end of or just after completing the pulse phase of the VAN-TP regimen that resolved spontaneously, usually within a day, and these episodes were not considered rCDI. If they developed progressive symptoms, a stool specimen for C. difficile testing was requested and appropriate CDI treatment was initiated.
The chart review collected demographic data as well as prior treatments, underlying illnesses, details of the VAN-TP regimen, concomitant medication, and clinical outcomes. Continuous data were analyzed by Student t test and categorical data were compared using χ 2 and Fisher exact tests. This study was approved by the Institutional Review Board for Human Studies at Loyola.
RESULTS
Among 131 consecutive patients treated with VAN-TP for rCDI, 31 were excluded from analysis: 9 were lost to follow-up, 7 had no symptomatic response to vancomycin during the treatment or taper phases making rCDI an unlikely diagnosis, 5 did not adhere to the prescribed regimen, 4 had active inflammatory bowel disease confounding treatment response, 2 patients died from unrelated illness before completing their regimens, 3 were kept on long suppressive vancomycin dosing (once daily) during chemotherapy or procedures where concomitant antibiotics were administered, and 1 patient entered hospice care before completing the VAN-TP regimen.
Of the remaining 100 patients, 64% were female and the mean number of prior CDI episodes was 3.15 ± 1.3 (Table 1 ). All patients tapered oral vancomycin to once daily (Table 2) , with 36 receiving QOD and 64 receiving QOD + Q3D pulse dosing after the taper. The mean length of treatment overall was 77 ± 29.9 days: 60.3 ± 25.9 for the QOD group and 86.3 ± 27.8 days for the QOD + Q3D group (P = .0004). Patients in the QOD + Q3D group were older (P = .02) and more likely to have had prior treatment with vancomycin taper and/or pulse (P = .03). Patients in the QOD group were more likely to have had prior vancomycin treatment without a taper or pulse (P = .02).
Recurrence of diarrhea requiring retreatment occurred in 26% of patients following VAN-TP. Seven patients had Abbreviations: CDI, Clostridium difficile infection; Q3D, every third day; QOD, every other day; SD, standard deviation; VAN-TP, vancomycin taper and pulse. a Concomitant antibiotic use during VAN-TP treatment included trimethoprim-sulfamethoxazole (TMP-SMX) (n = 7) and dapsone (n = 1) for pneumonia prophylaxis in the immunocompromised patients; cephalexin (n = 2), TMP-SMX (n = 1), ciprofloxacin (n = 1), and nitrofurantoin (n = 1) for urinary tract infection; azithromycin for chronic lung disease (n = 2); rifaximin for hepatic encephalopathy (n = 1); doxycycline, cefazolin, intravenous vancomycin, and cephalexin for a prosthetic joint infection (n = 1); levofloxacin for pneumonia (n = 1); cephalexin for diabetic foot ulcer (n = 1); ethambutol and rifabutin for Mycobacterium avium complex pulmonary infection (n = 1).
Table 2. Duration of Taper and Pulse Phases in Patients With Recurrent Clostridium difficile Infection Treated With a Vancomycin Taper and Pulse Regimen
Taper/Pulse Phase QOD (n = 36) QOD + Q3D (n = 64) P Value Total; Range (N = 100) 
DISCUSSION
Although there is increasing availability of new treatment agents [7, 8] and use of fecal microbiota transplantation (FMT) [9] for managing rCDI patients, vancomycin has been a mainstay of treatment for this indication. Despite the frequency of use and guideline recommendations, there are surprisingly few studies in the literature describing VAN-TP regimens and outcomes, and until recently, no randomized controlled trials [10] .
In this study, we investigated the efficacy of VAN-TP among 100 patients with rCDI at our referral clinic over a 5-year period. VAN-TP was found to be very effective in treating rCDI, with a cure rate of 74% overall. Even a more conservative estimate of efficacy counting the excluded cases in our review as failures resulted in a 56% cure rate (74/131). This cure rate compared favorably to the cure rate achieved with both the VAN-TP regimen and FMT in a recent randomized, controlled trial of FMT by enema and VAN-TP [10] . Among patient and treatment factors analyzed, sex, age, concomitant antibiotics, gastric acid suppressant use, and total duration of VAN-TP treatment did not appear to influence cure rates. However, VAN-TP regimens that ended with Q3D dosing had significantly higher cure rates (81.1%) than those ending with QOD dosing (61.1%). In addition, there was a trend for improved cure rates among patients with ≤2 prior CDI episodes compared to those with ≥3 prior CDI episodes. Factors associated with prescribing QOD + Q3D over QOD only were older age and prior administration of a vancomycin taper and/or pulse regimen. Previous observational studies have reported outcomes for vancomycin tapers, pulse regimens, or combined taper and pulse regimens for rCDI, although the number of patients was small and the duration of follow-up was variable [2, 3] . In an uncontrolled prospective study, Majors and Ellis employed a VAN-TP regimen of 6 weeks' duration ending with QOD dosing in patients with initial CDI episodes in an attempt to reduce hospital readmissions for rCDI [11] . Three of 31 (9.7%) patients were readmitted for rCDI. Recently Hota et al reported the results of a randomized controlled trial of FMT vs VAN-TP that was stopped early for futility [10] . In this study, 56% of patients randomized to FMT by enema had a subsequent rCDI episode, compared to only 42% of patients who received the 6-week VAN-TP regimen.
Our VAN-TP regimens generally followed the IDSA guidelines, which suggest treating symptomatic rCDI with oral vancomycin for 10-14 days with 4 times a day dosing, followed by tapering to twice-daily dosing for 7 days, then once-daily dosing for 7 days, followed by QOD or Q3D dosing for 2-8 weeks, or 6-12 weeks in total duration [1] . The duration of our VAN-TP regimen was 11 weeks on average, but much longer for some patients. Although it has been suggested in a previous study that longer courses of vancomycin pulse regimens tended to lead to improved cure rates [3] , our results showed similar cure rates for those who received VAN-TP regimens <10 weeks and ≥10 weeks in duration, suggesting that longer treatment courses do not necessarily translate into better cure rates.
Our finding of improved cure rates with QOD + Q3D dosing over QOD dosing is consistent with the hypothesis that pulse dosing promotes a cyclical decrease in spore burden while also permitting the reestablishment of normal microbiota [2, 12] . Extension of the pulse regimen from QOD to Q3D might promote more thorough clearance of spores by allowing more time between dosing for spore germination and eradication of the resultant vegetative organisms.
Conclusions in our study are limited because this was a retrospective, nonrandomized observational study, and included patients treated at a single referral clinic. Despite these limitations, VAN-TP with careful follow-up can be a very effective treatment strategy for patients with rCDI, and this strategy warrants further study. A randomized, double-blinded, controlled trial that investigates VAN-TP for the treatment of rCDI is currently being conducted through the Veterans Administration Cooperative Studies Program (CSP 596; ClinicalTrials.gov identifier NCT02667418). This trial compares a standard 10-day course of vancomycin to a 10-day course of fidaxomicin and a 10-day course of vancomycin followed by a taper and pulse vancomycin regimen. 
